Literature DB >> 18420827

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura.

Jin Yu1, Susanne Heck, Vivek Patel, Jared Levan, Yu Yu, James B Bussel, Karina Yazdanbakhsh.   

Abstract

Immune thrombocytopenic purpura (ITP) is characterized by the presence of antiplatelet autoantibodies as a result of loss of tolerance. CD4+CD25+ regulatory T cells (Tregs) are important for maintenance of peripheral tolerance. Decreased levels of peripheral Tregs in patients with ITP have been reported. To test whether inefficient production or reduced immunosuppressive activity of Tregs contributes to loss of tolerance in patients with chronic ITP, we investigated the frequency and function of their circulating CD4+CD25(hi) Tregs. We found a com-parable frequency of circulating CD4+CD25(hi)Foxp3+ Tregs in patients and controls (n = 16, P > .05). However, sorted CD4+CD25(hi) cells from patients with chronic ITP (n = 13) had a 2-fold reduction of in vitro immunosuppressive activity compared with controls (n = 10, P < .05). The impaired suppression was specific to Tregs as shown by cross-mixing experiments with T cells from controls. These data suggest that functional defects in Tregs contribute to breakdown of self-tolerance in patients with chronic ITP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18420827      PMCID: PMC2515134          DOI: 10.1182/blood-2008-01-135335

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura.

Authors:  M Kuwana; J Kaburaki; H Kitasato; M Kato; S Kawai; Y Kawakami; Y Ikeda
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

2.  Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura.

Authors:  Bin Liu; Hui Zhao; Man-Chiu Poon; Zhibo Han; Dongsheng Gu; Maoqiang Xu; Hairong Jia; Renchi Yang; Zhong Chao Han
Journal:  Eur J Haematol       Date:  2007-02       Impact factor: 2.997

Review 3.  Dynamics of antigen-specific regulatory T-cells in the context of autoimmunity.

Authors:  Thomas Korn; Mohamed Oukka
Journal:  Semin Immunol       Date:  2007-04-16       Impact factor: 11.130

4.  Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura.

Authors:  Miho Sakakura; Hideo Wada; Isao Tawara; Tsutomu Nobori; Takashi Sugiyama; Norimasa Sagawa; Hiroshi Shiku
Journal:  Thromb Res       Date:  2006-10-24       Impact factor: 3.944

Review 5.  Immune pathophysiology of autoimmune thrombocytopenic purpura.

Authors:  J W Semple
Journal:  Blood Rev       Date:  2002-03       Impact factor: 8.250

6.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

7.  Multiple immuno-regulatory defects in type-1 diabetes.

Authors:  Anjli Kukreja; Giulia Cost; John Marker; Chenhui Zhang; Zhong Sun; Karen Lin-Su; Svetlana Ten; Maureen Sanz; Mark Exley; Brian Wilson; Steven Porcelli; Noel Maclaren
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 8.  CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases.

Authors:  Xavier Valencia; Peter E Lipsky
Journal:  Nat Clin Pract Rheumatol       Date:  2007-11

Review 9.  Immune thrombocytopenic purpura.

Authors:  Bethan Psaila; James B Bussel
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

10.  Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome.

Authors:  Yun Ling; Xiangshan Cao; Ziqiang Yu; Changgeng Ruan
Journal:  Eur J Haematol       Date:  2007-08-10       Impact factor: 2.997

View more
  69 in total

Review 1.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

2.  Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia.

Authors:  Jiang Cao; Chong Chen; Li Li; Zeng Ling-yu; Li Zhen-yu; Yan Zhi-ling; Chen Wei; Cheng Hai; Wei Sang; Xu Kai-lin
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

3.  Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.

Authors:  Zhenyu Li; Weiwei Mou; Guang Lu; Jiang Cao; Xupeng He; Xiuying Pan; Kailin Xu
Journal:  Int J Hematol       Date:  2010-12-29       Impact factor: 2.490

Review 4.  Advances in immunopathogenesis of adult immune thrombocytopenia.

Authors:  Xinguang Liu; Yu Hou; Jun Peng
Journal:  Front Med       Date:  2013-11-21       Impact factor: 4.592

5.  Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients.

Authors:  Doaa I Elzaeem; Esmat A El Sharkawi; Eman M Zaki; Ayman G Ghobrial; Aliaa S Abd El-Fatah; Waleed M Abd El-Hamed
Journal:  Ann Hematol       Date:  2021-05-13       Impact factor: 3.673

6.  Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura.

Authors:  Jingbo Zhang; Daoxin Ma; Xiaojuan Zhu; Xun Qu; Chunyan Ji; Ming Hou
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

Review 7.  Platelets and the immune continuum.

Authors:  John W Semple; Joseph E Italiano; John Freedman
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

Review 8.  Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.

Authors:  Carlo Perricone; Fulvia Ceccarelli; Gideon Nesher; Elisabetta Borella; Qasim Odeh; Fabrizio Conti; Yehuda Shoenfeld; Guido Valesini
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

9.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

Review 10.  Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.

Authors:  Shi-Yang Guan; Rui-Xue Leng; Muhammad Imran Khan; Humera Qureshi; Xiang-Pei Li; Dong-Qing Ye; Hai-Feng Pan
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.